G, P., C, P., C, G., A, P., E, R., G, M., . . . A, C. (2026). Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: The ELBA observational study. Frontiers in oncology, 16, 1724019. https://doi.org/10.3389/fonc.2026.1724019
Chicago Style (17th ed.) CitationG, Pasello, et al. "Real-world Description of Patients with Resected Epidermal Growth Factor Receptor Mutation Positive Non-small Cell Lung Carcinoma Treated with Adjuvant Osimertinib in an Early Access Program in Italy: The ELBA Observational Study." Frontiers in Oncology 16 (2026): 1724019. https://doi.org/10.3389/fonc.2026.1724019.
MLA (9th ed.) CitationG, Pasello, et al. "Real-world Description of Patients with Resected Epidermal Growth Factor Receptor Mutation Positive Non-small Cell Lung Carcinoma Treated with Adjuvant Osimertinib in an Early Access Program in Italy: The ELBA Observational Study." Frontiers in Oncology, vol. 16, 2026, p. 1724019, https://doi.org/10.3389/fonc.2026.1724019.
